Aptamer Sciences, Inc.
π°π·South Korea
- Country
- π°π·South Korea
- Ownership
- Public
- Established
- 2011-04-01
- Employees
- 39
- Market Cap
- -
- Website
- http://www.aptsci.com
Clinical Trials
1
Active:0
Completed:0
Trial Phases
1 Phases
Phase 1:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1 trials with phase data)β’ Click on a phase to view related trials
Phase 1
1 (100.0%)A Study to Evaluate the Tolerability, Safety, and PK of AST-201 in Patients with GPC3-positive Advanced Solid Tumors
Phase 1
Recruiting
- Conditions
- NeoplasmsCarcinoma, HepatocellularCarcinoma, Non-Small-Cell LungLiver Neoplasms
- Interventions
- First Posted Date
- 2024-11-14
- Last Posted Date
- 2025-03-21
- Lead Sponsor
- Aptamer Sciences, Inc.
- Target Recruit Count
- 70
- Registration Number
- NCT06687941
- Locations
- π°π·
National Cancer Center, Korea, Gyeonggi, Korea, Republic of
π°π·CHA Bundang Medical Center, Seongnam, Korea, Republic of
π°π·Severance Hospital, Seoul, Korea, Republic of
News
No news found